About
Improdia is a diagnostic company that develops clusters of novel proprietary biomarkers for monitoring the immunity status of patients suffering from diseases associated with chronic inflammation. The technology enables the tracking of disease regression, recurrence and treatment response, and immunity status. The technology will help to identify patients who are most likely to benefit from a particular therapeutic treatment and to predict the occurrence of complications before they are evident. Improdia's technology has potential as a prognostic/diagnostic kit for a wide range of chronic inflammatory diseases and as a key tool for pharmaceutical companies in the development of new drugs for cancer, Alzheimer's disease, heart disease, rheumatology, and pulmonary diseases. Improdia's R&D focuses on developing a clinical prototype that can be successfully used in multi-center trials. The emphasis of the work revolves around product establishment and characterization, process standardization, and quality control validation. Improdia was established based on a project conceived in the Department of Immunology under Professor Michal Baniyash at the Hebrew University of Jerusalem.
Funding history · 1 round · $200K total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When was ImProDia founded?
- ImProDia was founded in January 2012.
- What is ImProDia's primary focus?
- ImProDia is a diagnostic company developing novel proprietary biomarkers for monitoring the immunity status of patients with chronic inflammation-associated diseases.
- Where is ImProDia headquartered?
- ImProDia is headquartered in Herzliya, Israel.
- What was ImProDia's first significant funding event?
- In June 2012, ImProDia received a grant of $200,000 from the IIA.
- When did ImProDia raise its Seed round and who was an investor?
- ImProDia raised a Seed round in October 2014, with Citrine S A L participating as an investor.
- What is the current employee count for ImProDia?
- ImProDia currently has 1-10 employees.
- What is the origin of ImProDia's technology?
- ImProDia's technology originated from a project conceived in the Department of Immunology under Professor Michal Baniyash at the Hebrew University of Jerusalem.
- What is the product stage of ImProDia's technology?
- ImProDia's technology is currently in the clinical trial stage.
- What are ImProDia's target geographic markets?
- ImProDia targets geographic markets in Europe and India.